ZELTIQ® Aesthetics Intellectual Property and Patents Validated in Settlement against SkinSpaMed

ZELTIQ Aesthetics, Inc. (Nasdaq: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced it has accepted a settlement from SkinSpaMed. In February of this year, the United States District Court for the Northern District of Texas, Dallas Division, granted ZELTIQ a preliminary injunction prohibiting SkinSpaMed from issuing false and misleading statements regarding its imitation “Fat Freeze Cryolipolysis” services.

“We are pleased to have reached this settlement,” said Mark Foley, President and Chief Executive Officer of ZELTIQ. “ZELTIQ will continue to vigorously protect its intellectual property and defend its brand against unfair business practices.”

ZELTIQ is the exclusive licensee of Cryolipolysis, the patented technology behind the aesthetic procedure marketed as CoolSculpting®. Cryolipolysis is the non-invasive cooling of adipose tissue to induce lipolysis – the breaking down of fat cells – to reduce body fat without damage to other tissues.

“Whether in the United States or internationally, ZELTIQ is strongly committed to protecting its intellectual property rights and its reputation for safety and efficacy,” said Sergio Garcia, ZELTIQ Senior Vice President, General Counsel and Corporate Secretary. “To date, CoolSculpting is the only Cryolipolysis treatment that has received FDA clearance. Consumers should be aware of the potential dangers of non FDA-cleared copycat devices.”


ZELTIQ® Aesthetics, Inc. (Nasdaq: ZLTQ) is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ’s first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.


Shari Gold
Mark Foley
President and CEO
The Ruth Group for ZELTIQ
Nick Laudico / Amy Glynn
646-536-7030 / 7023
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here